Tocilizumab for the treatment of rheumatoid arthritis

References

• Kishimoto T. The biology of interleukin-6. Blood74(1), 1–10 (1989).
   PubMed Web of Science ®Google Scholar
• Kishimoto T. Interleukin-6: from basic science to medicine – 40 years in immunology. Annu. Rev. Immunol.23, 1–21 (2005).
   PubMed Web of Science ®Google Scholar
• Tanaka T, Katada Y, Suemura M, Kishimoto T. Interleukin-6. In: Cytokine Regulation of Humoral Immunity: Basic and Clinical Aspects. Snapper CM (Ed.). John Wiley & Sons Ltd., Chichester, UK, 251–272 (1996).
   Google Scholar
• Kopf M, Baumann H, Freer G et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature368, 339–342 (1994).
   PubMed Web of Science ®Google Scholar
• Murakami M, Hibi M, Nakagawa N et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science260, 1808–1810 (1993).
   PubMed Web of Science ®Google Scholar
• Narazaki M, Witthuhn BA, Yoshida K et al. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc. Natl Acad. Sci. USA91(6), 2285–2289 (1994).
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood86(4), 1243–1254 (1995).
   PubMed Web of Science ®Google Scholar
• Naka T, Narazaki M, Hirata M et al. Structure and function of a new STAT-induced STAT inhibitor. Nature387, 924–929 (1997).
   PubMed Web of Science ®Google Scholar
• Narazaki M, Yasukawa K, Saito T et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood82(4), 1120–1126 (1993).
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell76(2), 253–262 (1994).
   PubMed Web of Science ®Google Scholar
• Hirano T, Taga T, Yasukawa K et al. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc. Natl Acad. Sci. USA84(1), 228–231 (1987).
   PubMed Web of Science ®Google Scholar
• Yoshizaki K, Matsuda T, Nishimoto N et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood74(4), 1360–1367 (1989).
   PubMed Web of Science ®Google Scholar
• Hirano T, Matsuda T, Turner M et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol.18, 1797–1801 (1988).
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet370, 1861–1874 (2007).
   PubMed Web of Science ®Google Scholar
• Ohshima S, Saeki Y, Mima T et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl Acad. Sci. USA95(14), 8222–8226 (1998).
   PubMed Web of Science ®Google Scholar
• Choy EH, Isenberg DA, Garrood T et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum.46, 143–150 (2002).
   Google Scholar
• Nishimoto N, Yoshizaki K, Maeda K et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol.30, 1426–1435 (2003).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum.50, 1761–1769 (2004).
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum.54, 2817–2829 (2006).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis.68, 1580–1584 (2009).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumab. Ann. Rheum. Dis.66, 1162–1167 (2007).
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with TCZ reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the TCZ in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum.58, 2968–2980 (2008).
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with TCZ improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomized placebo controlled trial. Ann. Rheum. Dis.67(11), 1516–1523 (2008).
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet371, 987–997 (2008).
   PubMed Web of Science ®Google Scholar
• Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum.62, 33–43 (2010).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol.19, 12–19 (2009).
   PubMed Web of Science ®Google Scholar
• Fleischmann R. LITHE: Tocilizumab inhibits radiographic progression and improves physical function in rheumatoid arthritis (RA) patients at 2 years with increasing clinical efficacy over time. Presented at: American College of Rheumatology Meeting. Pennsylvania, PA, USA, 17–21 October 2009 (Abstract 637).
   Google Scholar
• Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis.69, 88–96 (2010).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod. Rheumatol.20(3), 222–232 (2010).
   PubMed Web of Science ®Google Scholar
• Intermediate Report of Post-Marketing Surveillance: Safety Information about ACTEMRA Volume 2. Chugai Pharm. Co., Japan (2009).
   Google Scholar
• Koike R, Harigai M, Atsumi T et al. Japanese College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod. Rheumatol.19, 351–357 (2009).
   PubMed Web of Science ®Google Scholar
• Nam JL, Winthrop KL, van Vollenhoven RF et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis.69(6), 976–986 (2010).
   PubMed Web of Science ®Google Scholar
• Gause A, Rubbert-Roth A, Michels H et al. [Recommendations of the German Rheumatology Society on the use of tocilizumab in rheumatoid arthritis]. Z. Rheumatol.69(4), 365–372 (2010).
   PubMedGoogle Scholar
• Fonseca JE, Canhao H, Reis P et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis – March 2010 update. Acta Rheumatol. Port.35(1), 95–98 (2010).
   PubMedGoogle Scholar
• Moots RJ, Ostor AJK, Isaacs JD. Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the ‘age of remission’? Expert Opin. Investig. Drugs18(11), 1687–1699 (2009).
   PubMed Web of Science ®Google Scholar
• Marti L, Scheinberg M. Anti-interleukin 6: a first line in rheumatoid arthritis? Clin. Rheumatol.27, 877–879 (2009).
   Google Scholar
• Scheinecker C, Smolen J, Yasothan U, Stoll J, Kirkpatrick P. Tocilizumab. Nat. Rev. Drug Discov.8, 273–274 (2009).
   PubMed Web of Science ®Google Scholar
• Smolen JS, Weinblatt ME. When patients with rheumatoid arthritis fail tumor necrosis factor inhibitors: what is the next step? Ann. Rheum. Dis.67, 1497–1498 (2008).
   PubMed Web of Science ®Google Scholar
• Van Ingen J, Boeree MJ, Dekhuizen PN, van Soolingen D. Mycobacterial diseases in patients with rheumatic disease. Nat. Clin. Pract. Rheumatol.4(12), 649–656 (2008).
   PubMedGoogle Scholar
• Ogata A, Mori M, Hashimoto S et al. Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens. Mod. Rheumatol.20, 130–133 (2010).
   PubMed Web of Science ®Google Scholar
• Ohsugi Y, Kishimoto T. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther.8(5), 669–681 (2008).
   PubMed Web of Science ®Google Scholar
• Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system Biochem. Biophys. Res. Commun.314, 363–369 (2004).
   PubMed Web of Science ®Google Scholar
• Hagihara K, Nishikawa T, Sugamata Y et al. Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expression. Genes Cells10, 1051–1063 (2005).
   PubMed Web of Science ®Google Scholar
• Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum.54(9), 2997–3000 (2006).
   PubMed Web of Science ®Google Scholar
• Nishida S, Hagihara K, Shima Y et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann. Rheum. Dis.68, 1235–1236 (2009).
   PubMed Web of Science ®Google Scholar
• Sato H, Sakai T, Sugaya T et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin. Rheumatol.28(9), 1113–1116 (2009).
   PubMed Web of Science ®Google Scholar
• Inoue D, Arima H, Kawanami C et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin. Rheumatol.29(10), 1195–1197 (2010).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood112(10), 3959–3964 (2008).
   PubMed Web of Science ®Google Scholar
• Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology126(4), 989–996 (2004).
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthritis Rheum.46(12), 3388–3389 (2002).
   PubMed Web of Science ®Google Scholar
• Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years. Mod. Rheumatol.19(1), 69–72 (2009).
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Nagashima T, Takatori S et al. Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab. Clin. Rheumatol.24(4), 485–487 (2009).
   Google Scholar
• Yoshimura M, Makiyama J, Koga T et al. Successful treatment with tocilizumab in a patient with refractory adult-onset Still’s disease (AOSD). Clin. Exp. Rheumatol.28(1), 141–142 (2010).
   PubMed Web of Science ®Google Scholar
• De Bandt M, Saint-Marcoux B. Tocilizumab for multirefratory adult-onset Still’s disease. Ann. Rheum. Dis.68(1), 153–154 (2009).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum.58(4), 1197–1200 (2008).
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label Phase I dosage-escalation study. Arthritis Rheum.62(2), 542–552 (2010).
   PubMed Web of Science ®Google Scholar
• Kawai M, Hagihara K, Hirano T et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody in two patients with refractory relapsing polychondritis. Rheumatology48, 318–319 (2009).
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kuwahara Y, Shima Y et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum.61, 1762–1764 (2009).
   PubMed Web of Science ®Google Scholar
• Henes JC, Horger M, Guenaydin I, Kanz L, Koetter I. Mixed response to tocilizumab for ankylosing spondylitis. Ann. Rheum. Dis. DOI: 10.1136/ard.2009.126706 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Tanaka T, Hagihara K, Shima Y et al. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Rheumatology49, 824–826 (2010).
   PubMed Web of Science ®Google Scholar
• Hagihara K, Kawase I, Tanaka T, Kishimoto T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J. Rheumatol.37, 1075–1076 (2010).
   PubMed Web of Science ®Google Scholar
• Shima Y, Kuwahara Y, Murota H et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology DOI: 10.1093/rheumatology/keq275 (2010) (Epub ahead of print).
   Google Scholar